From Surf Wiki (app.surf) — the open knowledge base
Β-Hydroxythiofentanyl
Opioid analgesic drug
Opioid analgesic drug
| Field | Value | ||||
|---|---|---|---|---|---|
| drug_name | β-Hydroxythiofentanyl | ||||
| verifiedrevid | 410873709 | ||||
| IUPAC_name | N-{1-[2-Hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl}-N-phenylpropanamide | ||||
| image | Betahydroxythiofentanyl.svg | ||||
| image_class | skin-invert-image | ||||
| width | 200px | ||||
| pregnancy_AU | |||||
| pregnancy_US | |||||
| legal_AU | |||||
| legal_CA | Schedule I | ||||
| legal_UK | Class A | ||||
| legal_US | Schedule I | ||||
| CAS_number | 1474-34-6 | ||||
| UNII_Ref | |||||
| UNII | MG6JW60TUG | ||||
| ATC_prefix | none | ||||
| PubChem | 62278 | ||||
| DrugBank_Ref | |||||
| ChemSpiderID_Ref | |||||
| ChemSpiderID | 21106268 | ||||
| C | 20 | H=26 | N=2 | O=2 | S=1 |
| smiles | CCC(=O)N(c1ccccc1)C2CCN(CC2)CC(c3cccs3)O | ||||
| StdInChI_Ref | |||||
| StdInChI | 1S/C20H26N2O2S/c1-2-20(24)22(16-7-4-3-5-8-16)17-10-12-21(13-11-17)15-18(23)19-9-6-14-25-19/h3-9,14,17-18,23H,2,10-13,15H2,1H3 | ||||
| StdInChIKey_Ref | |||||
| StdInChIKey | GLAAETOTOUGGSB-UHFFFAOYSA-N |
| elimination_half-life =
β-Hydroxythiofentanyl (beta-hydroxythiofentanyl) is an opioid analgesic that is an analog of fentanyl and thiofentanyl.
β-Hydroxythiofentanyl was sold briefly on the black market from around 1985, before the introduction of the Federal Analog Act in 1986 which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared. β-hydroxythiofentanyl was anecdotally said to be one of the more favored fentanyl analogs by opiate addicts.
Side Effects
β-Hydroxythiofentanyl has effects and side effects similar to fentanyl. Side effects of fentanyl analogs include itching, nausea and potentially serious respiratory depression, which can be life-threatening.
Legal status
As of October 2015, β-hydroxythiofentanyl is a controlled substance in China.
As of May 2016, β-hydroxythiofentanyl was temporarily listed as a Schedule I controlled substance in the United States. A final ruling placing it in Schedule I was issued by the DEA on May 8, 2019 after a 1 year notice of proposed permanent scheduling. There were no petitions for hearings on the matter.
References
References
- Valter K, Arrizabalaga P. Designer Drugs Directory (1998), p150. {{ISBN. 0-444-20525-X
- (March 1988). "Designer drugs: past history and future prospects". Journal of Forensic Sciences.
- (November 2025). "In vitro and in vivo pharmacological characterization of fentanyl analogs". Neuropharmacology.
- (27 September 2015). "关于印发《非药用类麻醉药品和精神药品列管办法》的通知". China Food and Drug Administration.
- (12 May 2016). "Schedules of Controlled Substances: Temporary Placement of Butyryl Fentanyl and Beta-Hydroxythiofentanyl into Schedule I". [[Drug Enforcement Administration]].
- {{USC. 5. 556-557
- (May 8, 2019). "Schedules of Controlled Substances: Placement of beta-Hydroxythiofentanyl in Schedule I". Department of Justice.
- {{CodeFedReg. 21. 1308. 11. 17
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Β-Hydroxythiofentanyl — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report